Laboratory biomarkers for lung disease severity and progression in cystic fibrosis.
Biomarker
CRP
Cystic fibrosis
Drug efficacy
HE4
Inflammation
Pulmonary exacerbation
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
20
08
2019
revised:
20
04
2020
accepted:
07
05
2020
pubmed:
20
5
2020
medline:
22
6
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
Although the clinical outcomes of cystic fibrosis (CF) have been markedly improved through the recent implementation of novel CF transmembrane conductance regulator (CFTR) modulator drugs, robust and reliable biomarkers are still demanded for the early detection of CF lung disease progression, monitoring treatment efficacy and predicting life-threatening clinical complications. Thus, there is an unmet need to identify and validate novel, ideally blood based biomarkers with strong correlations to the severity of CF lung disease, which represents a major contribution to overall CF morbidity and mortality. In this review, we aim to summarize the utility of thus far studied blood-, sputum- and bronchoalveolar lavage (BAL)-based biomarkers to evaluate inflammatory conditions in the lung and to follow treatment efficacy in CF. Measurements of sweat chloride concentrations and the spirometric parameter FEV
Identifiants
pubmed: 32428503
pii: S0009-8981(20)30212-6
doi: 10.1016/j.cca.2020.05.015
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-286Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors have no direct or indirect conflict of interest which could affect the content and outcomes of this review.